Amylin Pharmaceuticals, Inc. Sinks After U.S. FDA Rejects Data
WASHINGTON, Nov 4 (Reuters) - Shares of Amylin Pharmaceuticals Inc fell more than 20 percent on Tuesday after the biotech company said in a regulatory filing that the U.S. Food and Drug Administration rejected data for an experimental version of its diabetes drug Byetta.